AR065098A1 - Regimen posologico para inhibidores de comt - Google Patents
Regimen posologico para inhibidores de comtInfo
- Publication number
- AR065098A1 AR065098A1 ARP080100382A ARP080100382A AR065098A1 AR 065098 A1 AR065098 A1 AR 065098A1 AR P080100382 A ARP080100382 A AR P080100382A AR P080100382 A ARP080100382 A AR P080100382A AR 065098 A1 AR065098 A1 AR 065098A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- term
- medicament
- oxygen
- optionally substituted
- Prior art date
Links
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003435 aroyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001589 carboacyl group Chemical group 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 abstract 1
- 101710151768 Aromatic-L-amino-acid decarboxylase Proteins 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 239000011630 iodine Chemical group 0.000 abstract 1
- 229910052740 iodine Chemical group 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 125000005000 thioaryl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Uso de un compuesto de oxodiazolilo para la preparacion de un medicamento para la prevencion o el tratamiento de trastornos asociados con el sistema nervioso central periférico, en donde dicho médicamente se administra de acuerdo con un régimen posologico que tiene una periodicidad de dosificacion que va de aproximadamente dos veces por día a una vez cada dos días. Reivindicacion 1: Uso de un compuesto de la formula (1) caracterizado porque R1 y R2 son iguales o diferentes y significan hidrogenos o grupos hidrolizables en condiciones fisiologicas, alcanoilo opcionalmente sustituido o aroílo; X significa un grupo metileno; Y representa un átomo de oxígeno, nitrogeno o azufre; n representa el numero 0, 1, 2 o 3 y m representa el numero 0 o 1; R3 significa un grupo N-oxido de piridina de acuerdo con la formula A, B o C, que está conectado como se indica por medio del enlace no marcado: donde R4, R5, R6 y R7 son iguales o diferentes, y significan hidrogeno, grupo alquilo inferior, tioalquilo inferior, alcoxi inferior, ariloxi o tioarilo, grupo alcanoilo inferior o aroílo, grupo arilo opcionalmente sustituido, amino, alquilamino inferior, dialquilamino inferior, cicloalquilamino o heterocicloalquilamino, grupo alquilsulfonilo arilsulfonilo inferior, halogeno, grupo haloalquilo, trifluorometilo, ciano, nitro o heteroarilo o tomados juntos significan anillos alifáticos o heteroalifáticos o aromáticos o heteroaromáticos; el término alquilo significa cadenas carbonadas, lineales o ramificadas, que contienen de uno a seis átomos de carbono; el término arilo significa un grupo fenilo o naftilo, opcionalmente sustituidos con grupos alcoxi o halogeno; el término heterocicloalquilo representa un anillo cíclico de cuatro a ocho miembros que opcionalmente incorpora otros átomos de oxígeno, azufre o nitrogeno; el término heteroarilo representa un anillo de cinco o seis miembros que opcionalmente incorpora un átomo de azufre, oxígeno o nitrogeno; el término halogeno representa fluor, cloro, bromo o yodo; o una e sus sales farmacologicamente aceptables, para preparar un medicamento para la prevencion o el tratamiento de trastornos asociados con el sistema nervioso central y periférico, en donde dicho medicamento se administra de acuerdo con un régimen posologico que tiene periodicidad de dosificacion que va de aproximadamente dos veces por día a aproximadamente una vez cada dos días. Reivindicacion 18: Envase de acuerdo con cualquiera de las reivindicaciones 10 1 17, caracterizado porque también comprende L-DOPA y/o AAAD y las instrucciones también incluyen instrucciones sobre la administracion de L-DOPA y/o AADC.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07002091 | 2007-01-31 | ||
| PCT/PT2007/000043 WO2008094053A1 (en) | 2007-01-31 | 2007-10-10 | Dosage regimen for comt inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065098A1 true AR065098A1 (es) | 2009-05-13 |
Family
ID=38961862
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100382A AR065098A1 (es) | 2007-01-31 | 2008-01-30 | Regimen posologico para inhibidores de comt |
| ARP170102484A AR109590A2 (es) | 2007-01-31 | 2017-09-08 | Régimen posológico para inhibidores de comt |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102484A AR109590A2 (es) | 2007-01-31 | 2017-09-08 | Régimen posológico para inhibidores de comt |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8524746B2 (es) |
| EP (2) | EP2124947B1 (es) |
| JP (1) | JP5517629B2 (es) |
| KR (1) | KR101522157B1 (es) |
| CN (1) | CN101631548B (es) |
| AR (2) | AR065098A1 (es) |
| AU (1) | AU2007346018A1 (es) |
| BR (1) | BRPI0721213B1 (es) |
| CA (1) | CA2678391C (es) |
| CY (1) | CY1118311T1 (es) |
| DK (2) | DK2124947T3 (es) |
| ES (2) | ES2597705T3 (es) |
| HR (1) | HRP20161261T8 (es) |
| HU (1) | HUE031317T2 (es) |
| IL (1) | IL200020A (es) |
| LT (1) | LT2481410T (es) |
| MX (1) | MX2009008051A (es) |
| NO (1) | NO20092905L (es) |
| PL (1) | PL2481410T3 (es) |
| PT (2) | PT2481410T (es) |
| RU (1) | RU2518483C2 (es) |
| SI (1) | SI2481410T1 (es) |
| WO (1) | WO2008094053A1 (es) |
| ZA (1) | ZA200905940B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL169855A (en) * | 2005-07-25 | 2014-05-28 | Elta Systems Ltd | A system and method for locating a receiver location |
| NZ565460A (en) | 2005-07-26 | 2011-06-30 | Bial Portela & Ca Sa | Nitrocatechol derivatives as COMT inhibitors |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| AU2007334436A1 (en) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
| PL2481410T3 (pl) | 2007-01-31 | 2017-03-31 | Bial - Portela & Ca., S.A. | Pochodne nitrokatecholu jako inhibitory COMT podawane w określonym schemacie dawkowania |
| KR20100126452A (ko) * | 2008-02-28 | 2010-12-01 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 난용성 약물용 약학적 조성물 |
| JP2011514380A (ja) * | 2008-03-17 | 2011-05-06 | バイアル−ポルテラ アンド シーエー，エス．エー． | ５−［３−（２，５−ジクロロ−４，６−ジメチル−１−オキシ−ピリジン−３−イル）［１，２，４］オキサジアゾール−５−イル］−３−ニトロベンゼン−１，２−ジオールの結晶形 |
| JP6165412B2 (ja) * | 2008-07-29 | 2017-07-19 | ノヴィファーマ，エス．アー． | ニトロカテコールの投与計画 |
| ES2915698T3 (es) * | 2009-04-01 | 2022-06-24 | Bial Portela & Ca Sa | Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para preparar las mismas |
| CN102448444B (zh) * | 2009-04-01 | 2016-05-25 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
| WO2011069075A2 (en) * | 2009-12-04 | 2011-06-09 | Grant Jon E | Treating impulse control disorders with catechol-o- methyl-transferase inhibitors |
| US20140045900A1 (en) * | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| WO2013089573A1 (en) | 2011-12-13 | 2013-06-20 | BIAL - PORTELA & Cª., S.A. | Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor |
| JP2018500300A (ja) | 2014-11-28 | 2018-01-11 | ノヴィファーマ，エス．アー． | パーキンソン病を遅延させるための医薬 |
| WO2016123577A1 (en) * | 2015-01-30 | 2016-08-04 | Lieber Institute For Brain Development | Comt inhibiting methods and compositions |
| WO2016123576A1 (en) | 2015-01-30 | 2016-08-04 | Lieber Institute For Brain Development | Comt inhibiting methods and compositions |
| HUE056356T2 (hu) | 2015-11-25 | 2022-02-28 | Lieber Inst Inc | Tetrahidro-8H-pirido[1,2-a]pirazin-8-on vegyületek, mint COMT inhibitorok neurodegeneratív rendellenességek kezelésére |
| EP3860603A1 (en) | 2018-10-05 | 2021-08-11 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| WO2020072884A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| USD912395S1 (en) * | 2019-11-01 | 2021-03-09 | Jondarius Brown | Apparatus for storing earphones |
| GB202204798D0 (en) | 2022-04-01 | 2022-05-18 | Bial Portela & Ca Sa | Prodrugs of opicapone |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US660753A (en) * | 1899-11-27 | 1900-10-30 | Ferdinand-Christoph Von Heydebrand Und Der Lasa | Artificial fuel. |
| US1532178A (en) * | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
| FR1260080A (fr) | 1960-03-22 | 1961-05-05 | Materiel De Forage Soc De Fab | Trépan à molettes étanche |
| US3647809A (en) * | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| US4022901A (en) * | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4386668A (en) * | 1980-09-19 | 1983-06-07 | Hughes Tool Company | Sealed lubricated and air cooled rock bit bearing |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| YU213587A (en) * | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| DE3840954A1 (de) | 1988-12-05 | 1990-06-07 | Shell Int Research | Herstellung von 2-chlornicotinsaeureestern |
| US5206372A (en) | 1990-06-05 | 1993-04-27 | Shell Research Limited | Preparation of 2-chloropyridine derivatives |
| EP0487774B1 (en) | 1990-11-29 | 1994-10-26 | Wei Ming Pharmaceutical Mfg. Co. Ltd. | A direct tabletting auxiliary |
| CA2126976A1 (en) | 1991-12-31 | 1993-07-08 | Hisashi Takasugi | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| GB9419274D0 (en) * | 1994-09-23 | 1994-11-09 | Orion Yhtymae Oy | New method for the preparation of 3,4-dihydroxy-5-nitrobenzaldehyde |
| DE19628617A1 (de) | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
| US6206110B1 (en) * | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
| CA2337755C (en) * | 1998-09-18 | 2008-07-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| KR100875222B1 (ko) | 1999-08-19 | 2008-12-19 | 아스트라제네카 아베 | 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도 |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| FI20000635A0 (fi) | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
| SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
| DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
| GB2363792A (en) | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
| AU2001280126A1 (en) | 2000-08-24 | 2002-03-04 | Sagawa Express Co., Ltd. | Card payment method for service charge concerning to physical distribution or transportation |
| CN1166626C (zh) | 2000-08-30 | 2004-09-15 | 李凌松 | 三或四取代苯基化合物、其制备方法及应用 |
| JP2004532611A (ja) | 2000-11-28 | 2004-10-28 | ザイモジェネティクス，インコーポレイティド | サイトカイン受容体ｚｃｙｔｏｒ１９ |
| US20040097555A1 (en) * | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| EP1354603A1 (en) | 2000-12-26 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| PL369598A1 (en) | 2001-02-21 | 2005-05-02 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1412327A2 (en) | 2001-05-30 | 2004-04-28 | LG Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| AU2002313633B2 (en) | 2001-06-08 | 2007-03-01 | Cytovia, Inc. | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs |
| PL208258B1 (pl) | 2001-07-26 | 2011-04-29 | Merck Patent Gmbh | Nowe zastosowanie 2-[5-(4-fluorofenylo) -3- pirydylometyloaminometylo] -chromanu oraz jego fizjologicznie tolerowanych soli |
| JP4379853B2 (ja) | 2001-10-05 | 2009-12-09 | 惠民製藥股▲分▼有限公司 | 直接錠剤化用調合物および補助剤の調合方法 |
| EP1581213A4 (en) * | 2002-12-18 | 2008-11-19 | Cytovia Inc | 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLE AND ANALOGUE TO ACTIVATE CASPASE AND INTRODUCTION OF APOPTOSIS AND THEIR USE |
| WO2005006945A2 (en) * | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| AU2004263148B2 (en) | 2003-08-06 | 2008-08-21 | Vertex Pharmaceuticals, Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| US7300406B2 (en) | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| EP1751133B1 (en) * | 2004-04-28 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| US20060173074A1 (en) | 2004-11-10 | 2006-08-03 | Juha Ellmen | Treatment of restless legs syndrome |
| EP1827453A1 (en) | 2004-12-06 | 2007-09-05 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
| JP2008525524A (ja) | 2004-12-28 | 2008-07-17 | アストラゼネカ・アクチエボラーグ | アリールスルホンアミドモジュレーター |
| US20080051441A1 (en) * | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
| AU2006239418A1 (en) | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
| US20060257473A1 (en) | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| ATE530519T1 (de) | 2005-06-03 | 2011-11-15 | Abbott Lab | Cyclobutylaminderivate |
| JP2007024970A (ja) | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
| US20090000437A1 (en) | 2005-07-14 | 2009-01-01 | Provo Craft And Novelty, Inc. | Methods for Cutting |
| NZ565460A (en) | 2005-07-26 | 2011-06-30 | Bial Portela & Ca Sa | Nitrocatechol derivatives as COMT inhibitors |
| GB0515327D0 (en) * | 2005-07-26 | 2005-08-31 | Portela & Ca Sa | Comt inhibitors |
| FR2889525A1 (fr) * | 2005-08-04 | 2007-02-09 | Palumed Sa | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. |
| US20070048384A1 (en) * | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
| EP1954137A4 (en) * | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE |
| WO2007063946A1 (ja) * | 2005-11-30 | 2007-06-07 | Fujifilm Ri Pharma Co., Ltd. | アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬 |
| GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
| US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US20080167286A1 (en) * | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| PL2481410T3 (pl) | 2007-01-31 | 2017-03-31 | Bial - Portela & Ca., S.A. | Pochodne nitrokatecholu jako inhibitory COMT podawane w określonym schemacie dawkowania |
| WO2009029632A1 (en) | 2007-08-27 | 2009-03-05 | Helicon Therapeutics, Inc. | Therapeutic isoxazole compounds |
| KR20100126452A (ko) * | 2008-02-28 | 2010-12-01 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 난용성 약물용 약학적 조성물 |
| JP2011514380A (ja) | 2008-03-17 | 2011-05-06 | バイアル−ポルテラ アンド シーエー，エス．エー． | ５−［３−（２，５−ジクロロ−４，６−ジメチル−１−オキシ−ピリジン−３−イル）［１，２，４］オキサジアゾール−５−イル］−３−ニトロベンゼン−１，２−ジオールの結晶形 |
| JP6165412B2 (ja) | 2008-07-29 | 2017-07-19 | ノヴィファーマ，エス．アー． | ニトロカテコールの投与計画 |
| ES2915698T3 (es) | 2009-04-01 | 2022-06-24 | Bial Portela & Ca Sa | Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para preparar las mismas |
| CN102448444B (zh) | 2009-04-01 | 2016-05-25 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
| AU2011222856B2 (en) | 2010-03-04 | 2015-10-15 | Orion Corporation | Use of levodopa, carbidopa and entacapone for treating Parkinson's disease |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| WO2013089573A1 (en) | 2011-12-13 | 2013-06-20 | BIAL - PORTELA & Cª., S.A. | Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor |
-
2007
- 2007-10-10 PL PL12163797T patent/PL2481410T3/pl unknown
- 2007-10-10 KR KR1020097016752A patent/KR101522157B1/ko active Active
- 2007-10-10 MX MX2009008051A patent/MX2009008051A/es active IP Right Grant
- 2007-10-10 ES ES12163797.9T patent/ES2597705T3/es active Active
- 2007-10-10 EP EP07834911.5A patent/EP2124947B1/en active Active
- 2007-10-10 CA CA2678391A patent/CA2678391C/en active Active
- 2007-10-10 BR BRPI0721213-5A patent/BRPI0721213B1/pt active IP Right Grant
- 2007-10-10 JP JP2009548186A patent/JP5517629B2/ja active Active
- 2007-10-10 US US12/524,848 patent/US8524746B2/en active Active
- 2007-10-10 LT LTEP12163797.9T patent/LT2481410T/lt unknown
- 2007-10-10 SI SI200731839A patent/SI2481410T1/sl unknown
- 2007-10-10 WO PCT/PT2007/000043 patent/WO2008094053A1/en not_active Ceased
- 2007-10-10 EP EP12163797.9A patent/EP2481410B1/en active Active
- 2007-10-10 PT PT121637979T patent/PT2481410T/pt unknown
- 2007-10-10 RU RU2009132188/04A patent/RU2518483C2/ru active
- 2007-10-10 ES ES07834911.5T patent/ES2644049T3/es active Active
- 2007-10-10 DK DK07834911.5T patent/DK2124947T3/da active
- 2007-10-10 PT PT78349115T patent/PT2124947T/pt unknown
- 2007-10-10 CN CN200780050737.2A patent/CN101631548B/zh active Active
- 2007-10-10 AU AU2007346018A patent/AU2007346018A1/en not_active Abandoned
- 2007-10-10 HU HUE12163797A patent/HUE031317T2/hu unknown
- 2007-10-10 DK DK12163797.9T patent/DK2481410T3/en active
-
2008
- 2008-01-30 AR ARP080100382A patent/AR065098A1/es not_active Application Discontinuation
-
2009
- 2009-07-22 IL IL200020A patent/IL200020A/en active IP Right Grant
- 2009-08-27 ZA ZA200905940A patent/ZA200905940B/xx unknown
- 2009-08-28 NO NO20092905A patent/NO20092905L/no not_active Application Discontinuation
-
2013
- 2013-07-25 US US13/950,661 patent/US20130331416A1/en not_active Abandoned
-
2015
- 2015-04-17 US US14/689,397 patent/US9745290B2/en active Active
-
2016
- 2016-10-03 HR HRP20161261TT patent/HRP20161261T8/hr unknown
- 2016-10-12 CY CY20161101012T patent/CY1118311T1/el unknown
-
2017
- 2017-09-08 AR ARP170102484A patent/AR109590A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065098A1 (es) | Regimen posologico para inhibidores de comt | |
| ES2723729T3 (es) | Régimen de administración de nitrocatecoles | |
| AR029815A1 (es) | Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamento | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| UY28578A1 (es) | Derivados de amida | |
| AR087309A1 (es) | Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis | |
| FR3037958B1 (fr) | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| AR078786A1 (es) | Derivados de la cromenona | |
| EA202090932A1 (ru) | Способы введения некоторых vmat2-ингибиторов | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| JP2011500506A5 (es) | ||
| MX386251B (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
| AR071069A1 (es) | Derivados sustituidos de pirazol y su uso para la prevencion o el tratamiento de cancer | |
| AR070220A1 (es) | Amino-bencimidazoles sustituidos medicamentos que comprenden dicho compuestos, uso y metodos de fabricacion de los mismos | |
| AR078114A1 (es) | Derivados de cromona, procesos para su preparacion y aplicaciones terapeuticas de los mismos | |
| ECSP22036502A (es) | Inhibidores del factor d del complemento para administraci?n oral | |
| AR053082A1 (es) | DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS. | |
| CY1118057T1 (el) | Φαρμακευτικη συνθεση για στοματικη χορηγηση | |
| CL2022000889A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| CY1116161T1 (el) | Kit για παρεντερικη χορηγηση φαρμακων | |
| AR022413A1 (es) | Utilizacion de derivados de piridazino(4,5-b)indol-1-acetamida, para la preparacion de medicamentos destinados a las enfermedades del sistema nerviosocentral | |
| MX2022006596A (es) | Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina. | |
| AR057906A1 (es) | Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. | |
| ATE526012T1 (de) | Pharmazeutische formulierungen von meloxicam | |
| AR040239A1 (es) | Tiofenos sustituidos, metodos para su preparacion, su uso para preparar un medicamento y medicamentos que los comprenden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |